This week has been a rollercoaster for ASX investors.
Monday saw the biggest sell-off in almost a year, as investor sentiment was extremely defensive due to developing conflict in the Middle East.
It felt as though this was the beginning of an extended decline, as many investors positioned themselves for a risk-off period.
However before the market crash could even begin, it bounced back yesterday.
The Motley Fool's Bernd Struben explained in detail yesterday the factors that are influencing this volatility.
While investors were able to breathe a momentary sigh of relief, there are likely more ups and downs to come.
Image source: Getty Images
What happened to these shares yesterday?
The S&P/ASX 200 Index (ASX: XJO) finished Tuesday a full 1% higher than Monday.
Two ASX shares that vastly outperformed the benchmark index were 4DMedical Ltd (ASX: 4DX) and Life360 Inc (ASX: 360).
These stocks rose 9.11% and 10.34% respectively.
This came after crashes of 5% and 7% on Monday.
What's more interesting, is these companies are part of two of Australia's worst performing ASX sectors this year: healthcare and technology.
Following this week's turbulence, 4DMedical shares are down 2.4% year to date, and up more than 1,000% in the last 12 months.
Meanwhile, Life360 shares are down 30% year to date and down 2% over the last 12 months.
With so much movement, it can be difficult for prospective investors to identify an attractive entry point.
Here is the latest guidance from analysts.
Life360 shares
For those unfamiliar, Life360's core product is a private family and friends social networking app that allows users to communicate and share their locations.
It was a strong performer across 2024-2025, however has been heavily sold off this year, most recently on the back of disappointing results.
It closed yesterday at $22.51.
Based on guidance from brokers, it now looks like an attractive buy.
Investors will be hoping it has finally hit rock bottom after a tough start to 2026.
Bell Potter has a recent target of $40.00.
Recently, Morgan Stanley put an overweight rating and $50.00 price target on Life360 shares.
These targets indicate an upside in the range of 77% to 122%.
Based on this guidance, it seems yesterday's spike could be the beginning of a recovery for Life360 shares.
Can 4DMedical keep rising?
4DMedical has been one of the hottest ASX shares over the last year.
It closed yesterday at $4.43 per share, an astounding 1,035.90% higher than 12 months ago.
It is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.
Despite yesterday's 9% rise, it seems analysts largely see the current share price as hovering close to fair value.
Analysts forecasts via TradingView have an average one year price target of $4.20 on this ASX stock.
That's approximately 5% lower than yesterday's price target.
